Shots:
The MHRA, TGA & Health Canada have granted marketing authorization for Kimmtrak to treat HLA-A*02:01+ adult patients with unresectable or mUM
The approvals were based on the results from the P-III (IMCgp100-202) trial evaluating Kimmtrak vs pembrolizumab, ipilimumab, or dacarbazine in a ratio (2:1) in 378 patients which showed an OS benefit with m-OS of 22mos., OS in the ITT population favored Kimmtrak compared to (82% pembrolizumab; 13% ipilimumab; 6% dacarbazine)
Patients also stopped taking treatment because of disease progression unless they were getting any other benefit, or for sev. toxicity, TRAEs were manageable & consistent with the proposed MoA, and no Grade 4 CRS events were reported
Ref: Globenewswire| Image: Immunocore
